.svg)
We are scientists, clinicians, engineers, AI experts, and operators working with conviction to develop medicines that change how chronic disease is experienced.
Come build the future of biopharma with us.
Living
without limits
PharmaEssentia makes medicines for people with chronic blood cancers. Our therapies are designed to treat myeloproliferative neoplasms (MPNs) at the source. We want to help patients live full lives with disease in the background.
The first approved PV treatment that addresses the root cause of disease
BESREMi is designed to target the bone marrow, helping to manage blood cell counts in adults with polycythemia vera (PV).
A new era of interferon
Ropeginterferon alfa-2b is structurally distinct from first and second generation interferon. We’ve taken natural interferon and engineered it to extend its half life and enhance stability and purity
About us
Built to prove
PharmaEssentia is an independent global biopharmaceutical company founded in Taiwan in 2003. After over two decades of conviction, our founding team of scientist-executives have ushered in a new era of interferon immunotherapies for people with rare and chronic blood cancers. This is what our belief in our science became.
Today, PharmaEssentia’s story is still being written. We have an expanding pipeline, and commercial operations across North America, Europe, Japan, Korea, Hong Kong, Beijing, and Singapore.
%201.avif)
Careers
Join our team
The PharmaEssentia
Innovation Award
In partnership with Tech Tokyo, PharmaEssentia launched the PharmaEssentia Innovation Award to recognize and support early-stage scientific research with the potential to change medicine.
We believe that great science deserves to be found, funded, and brought into the world. Our inaugural program brought together judges from Harvard University and the University of Tokyo to evaluate the next generation of breakthrough science. This is the beginning of a long-term commitment to prizes, scholarships, and research support.
Newsroom
Latest updates
May 21, 2026
Newsroom
PharmaEssentia to Present New Clinical Data Supporting the Use of Ropeginterferon Alfa-2b in Essential Thrombocythemia at ASCO and
March 28, 2026
Newsroom
PharmaEssentia Partners with Japan's TECH-Tokyo to Host the Inaugural "PharmaEssentia Innovation Award"
March 26, 2026
Newsroom
FDA Confirms a PDUFA Goal Date of August 30, 2026 for the sBLA Submission of Ropeginterferon Alfa-2b-njft in Essential Thrombocythemia (ET)
March 1, 2026
Newsroom
PharmaEssentia Announces Japan Approval of High-Dose Dosing Regimen for BESREMi®
February 9, 2026
Newsroom
PharmaEssentia Announces Plans to Establish New U.S. Manufacturing Facility in Puerto Rico to Support Global Growth of BESREMi®
January 23, 2026
Newsroom